Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Ladiratuzumab vedotin + Trastuzumab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Ladiratuzumab vedotin | SGN-LIV1A | Ladiratuzumab vedotin (SGN-LIV1A) is an antibody-drug conjugate (ADC) comprised of an antibody targeting the zinc transporter LIV-1 linked to monomethyl auristatin E (MMAE), which delivers the cytotoxic agent to LIV1-positive cells, potentially resulting in inhibition of tumor growth (PMID: 25253783). | ||
Trastuzumab | Herceptin | Anti HER2 | HER2 (ERBB2) Antibody 76 | Herceptin (trastuzumab) is a monoclonal antibody, which binds ERBB2 (HER2) to induce tumor cellular cytotoxicity (PMID: 17611206). Herceptin (trastuzumab) is FDA approved for HER2-overexpressing (or amplification) breast cancer, gastric adenocarcinoma, and gastroesophageal junction adenocarcinoma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01969643 | Phase I | Ladiratuzumab vedotin Ladiratuzumab vedotin + Trastuzumab | A Safety Study of SGN-LIV1A in Breast Cancer Patients | Completed | USA | 0 |